Biological and Biochemical Evaluation of Isatin-Isoniazid Hybrids as Bactericidal Candidates against Mycobacterium tuberculosis

Tuberculosis remains a leading cause of mortality among infectious diseases worldwide, prompting the need to discover new drugs to fight this disease. We report here the design, synthesis, and antimycobacterial activity of isatin-mono/bis-isoniazid hybrids. ABSTRACT Tuberculosis remains a leading cause of mortality among infectious diseases worldwide, prompting the need to discover new drugs to fight this disease. We report here the design, synthesis, and antimycobacterial activity of isatin-mono/bis-isoniazid hybrids. Most of the compounds exhibited very high activity against Mycobacterium tuberculosis, with MICs in the range of 0.195 to 0.39 μg/ml, and exerted a more potent bactericidal effect than the standard antitubercular drug isoniazid (INH). Importantly, these compounds were found to be well tolerated at high doses (>200 μg/ml) on Vero kidney cells, leading to high selectivity indices. Two of the most promising hybrids were evaluated for activity in THP-1 macrophages infected with M. tuberculosis, among which compound 11e was found to be slightly more effective than INH. Overexpression of InhA along with cross-resistance determination of the most potent compounds, selection of resistant mutants, and biochemical analysis, allowed us to decipher their mode of action. These compounds effectively inhibited mycolic acid biosynthesis and required KatG to exert their biological effects. Collectively, this suggests that the synthesized isatin-INH hybrids are promising antitubercular molecules for further evaluation in preclinical settings.

[1]  L. Alderwick,et al.  Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives. , 2020, Bioorganic & medicinal chemistry.

[2]  A. Korkegian,et al.  InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis , 2020, bioRxiv.

[3]  H. Patel,et al.  Synthesis and in vitro antitubercular activity of pyridine analouges against the resistant Mycobacterium tuberculosis. , 2020, Bioorganic chemistry.

[4]  S. Yarmoluk,et al.  Novel isoniazid derivative as promising antituberculosis agent. , 2020, Future microbiology.

[5]  P. Sander,et al.  KatG as Counterselection Marker for Nontuberculous Mycobacteria , 2020, Antimicrobial Agents and Chemotherapy.

[6]  K. Chibale,et al.  The quest for the holy grail: new antitubercular chemical entities, targets and strategies , 2020, Drug discovery today.

[7]  K. C. Sivakumar,et al.  Acetylation of isoniazid - a novel mechanism of isoniazid resistance in Mycobacterium tuberculosis , 2020, bioRxiv.

[8]  C. Biot,et al.  A piperidinol-containing molecule is active against Mycobacterium tuberculosis by inhibiting the mycolic acid flippase activity of MmpL3 , 2019, The Journal of Biological Chemistry.

[9]  L. Chiarelli,et al.  Mechanochemical Synthesis and Biological Evaluation of Novel Isoniazid Derivatives with Potent Antitubercular Activity , 2017, Molecules.

[10]  Zhi Xu,et al.  Isoniazid derivatives and their anti-tubercular activity. , 2017, European journal of medicinal chemistry.

[11]  K. Dooley,et al.  The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. , 2017, The Lancet. Respiratory medicine.

[12]  S. Gobec,et al.  A new 'golden age' for the antitubercular target InhA. , 2017, Drug discovery today.

[13]  L. Hanna,et al.  Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. , 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[14]  Bharathkumar Inturi,et al.  Recent Advances and Structural Features of Enoyl‐ACP Reductase Inhibitors of Mycobacterium tuberculosis , 2016, Archiv der Pharmazie.

[15]  Paul W Smith,et al.  Direct inhibitors of InhA are active against Mycobacterium tuberculosis , 2015, Science Translational Medicine.

[16]  Vasyl Kovalishyn,et al.  Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity. , 2014, European journal of medicinal chemistry.

[17]  Beena,et al.  Synthesis of novel 1,2,3-triazole derivatives of isoniazid and their in vitro and in vivo antimycobacterial activity evaluation. , 2014, European journal of medicinal chemistry.

[18]  M. Daffé,et al.  Mycolic acids: structures, biosynthesis, and beyond. , 2014, Chemistry & biology.

[19]  M. Chifiriuc,et al.  Synthesis and bioevaluation of some new isoniazid derivatives. , 2013, Bioorganic & medicinal chemistry.

[20]  L. Kremer,et al.  Synthesis, Antitubercular Activity and Mechanism of Resistance of Highly Effective Thiacetazone Analogues , 2013, PloS one.

[21]  L. Kremer,et al.  Point Mutations within the Fatty Acid Synthase Type II Dehydratase Components HadA or HadC Contribute to Isoxyl Resistance in Mycobacterium tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.

[22]  James C. Sacchettini,et al.  Novel Inhibitors of InhA Efficiently Kill Mycobacterium tuberculosis under Aerobic and Anaerobic Conditions , 2011, Antimicrobial Agents and Chemotherapy.

[23]  Chun-ling Xiao,et al.  Synthesis and in vitro Antimycobacterial Activity of 8‐OCH3 Ciprofloxacin Methylene and Ethylene Isatin Derivatives. , 2011 .

[24]  Eric Arnoult,et al.  The challenge of new drug discovery for tuberculosis , 2011, Nature.

[25]  T. Baasov,et al.  Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance , 2010, Expert opinion on drug discovery.

[26]  Lian-Shun Feng,et al.  Synthesis and in vitro antimycobacterial activity of balofloxacin ethylene isatin derivatives. , 2010, European journal of medicinal chemistry.

[27]  B. Meunier,et al.  Hybrid molecules with a dual mode of action: dream or reality? , 2008, Accounts of chemical research.

[28]  Catherine Vilchèze,et al.  The mechanism of isoniazid killing: clarity through the scope of genetics. , 2007, Annual review of microbiology.

[29]  G. Besra,et al.  The Mycobacterium tuberculosis FAS‐II condensing enzymes: their role in mycolic acid biosynthesis, acid‐fastness, pathogenesis and in future drug development , 2007, Molecular microbiology.

[30]  G. Besra,et al.  EthA, a Common Activator of Thiocarbamide-Containing Drugs Acting on Different Mycobacterial Targets , 2007, Antimicrobial Agents and Chemotherapy.

[31]  Bing Chen,et al.  Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. , 2006, Vaccine.

[32]  C. Vilchèze,et al.  Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid , 2006, Nature Medicine.

[33]  P. Ortiz de Montellano,et al.  Superoxide reactivity of KatG: insights into isoniazid resistance pathways in TB. , 2004, Journal of the American Chemical Society.

[34]  Peter J. Tonge,et al.  The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  T. Aboul-Fadl,et al.  Synthesis, antitubercular activity and pharmacokinetic studies of some schiff bases derived from 1- alkylisatin and isonicotinic acid hydrazide (inh) , 2003, Archives of pharmacal research.

[36]  C. Locht,et al.  Inhibition of InhA Activity, but Not KasA Activity, Induces Formation of a KasA-containing Complex in Mycobacteria* , 2003, Journal of Biological Chemistry.

[37]  G. Besra,et al.  Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis , 2002, Molecular microbiology.

[38]  M. Nguyen,et al.  Mn(III) Pyrophosphate as an Efficient Tool for Studying the Mode of Action of Isoniazid on the InhA Protein of Mycobacterium tuberculosis , 2002, Antimicrobial Agents and Chemotherapy.

[39]  James C. Sacchettini,et al.  Inactivation of the inhA-Encoded Fatty Acid Synthase II (FASII) Enoyl-Acyl Carrier Protein Reductase Induces Accumulation of the FASI End Products and Cell Lysis of Mycobacterium smegmatis , 2000, Journal of bacteriology.

[40]  D Alland,et al.  Thiolactomycin and Related Analogues as Novel Anti-mycobacterial Agents Targeting KasA and KasB Condensing Enzymes inMycobacterium tuberculosis * , 2000, The Journal of Biological Chemistry.

[41]  Wilming,et al.  Spontaneous Formation of the Bioactive Form of the Tuberculosis Drug Isoniazid. , 1999, Angewandte Chemie.

[42]  J. Sacchettini,et al.  Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. , 1998, Science.

[43]  P. Schultz,et al.  Overexpression, Purification, and Characterization of the Catalase-peroxidase KatG from Mycobacterium tuberculosis* , 1997, The Journal of Biological Chemistry.

[44]  J C Sacchettini,et al.  Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. , 1995, Biochemistry.

[45]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[46]  S. Cole,et al.  The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis , 1992, Nature.

[47]  Chun-ling Xiao,et al.  Synthesis and in vitro antimycobacterial activity of 8-OCH(3) ciprofloxacin methylene and ethylene isatin derivatives. , 2011, European journal of medicinal chemistry.

[48]  J. Musser,et al.  Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. , 1998, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.